Pembrolizumab improves overall survival and progression-free survival as first-line treatment for squamous non-small cell lung cancer (NSCLC) in KEYNOTE-407 trial
The pivotal phase 3 KEYNOTE-407 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Carboplatin-paclitaxel or nab-Paclitaxel, as first-line treatment for metastatic squamous non-small cell lung cancer ( sNSCLC ), met the dual primary endpoints of overall survival ( OS ) and progression-free survival ( PFS ).
Based on an interim analysis conducted by the independent Data Monitoring Committee ( DMC ), treatment with Pembrolizumab in combination with chemotherapy resulted in significantly longer overall survival and progression-free survival than chemotherapy alone.
The safety profile of Pembrolizumab in this combination was consistent with that previously observed in lung cancer.
Pembrolizumab is an anti-PD-1 therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells.
Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
KEYNOTE-407 is a randomized, double-blind, placebo-controlled, phase 3 study, investigating Pembrolizumab in combination with Carboplatin-Paclitaxel or nab-Paclitaxel, compared with Carboplatin-Paclitaxel or nab-Paclitaxel alone, in 560 untreated patients with metastatic squamous NSCLC.
Patients were required to have no previous systemic therapy for advanced disease.
The dual primary endpoints were overall survival and progression-free survival; secondary endpoints included objective response rate ( ORR ), which was alpha-controlled in a cohort of the first 200 patients, and duration of response ( DOR ). ( Xagena )
Source: Merck, 2018